Literature DB >> 34950371

Does Duration of Symptoms Reliably Predict Detection of Left Atrial Thrombus in Newly Diagnosed Atrial Fibrillation.

Ali Sakhnini1,2, Shemy Carasso1,2, Zyad Abu Znait1,2, Shalabi Amjad1,2, Lisa Grossman1,2, Ibrahim Marai1,2.   

Abstract

BACKGROUND: Large prospective trials attribute minimal thromboembolic risk for cardioversion of atrial fibrillation (AF) when duration of symptoms is shorter than 48 hours. Our goal is to compare the prevalence of left atrial appendage (LAA) thrombus as demonstrated by a Trans esophageal echocardiography (TEE) exam between patients presenting with less or more than 48 hours of AF symptoms.
METHODS: Observational cohort study including consecutive patients hospitalized with primary diagnosis of new onset AF, not previously treated with oral anticoagulation. All patients underwent TEE to exclude LAA thrombus, regardless of symptoms duration. Patients were divided into two groups based on AF duration: 1) early presenters: up to 48 hours, 2) later presenters: longer than 48 hours.
RESULTS: The study included 122 patients mean age 65.8 years). The "early presenters" were younger, with less co-morbidities. LAA thrombus was detected in 13(21%) of 62 early presenters, compared to 20 (33%) of 60 patients of the second group (P=0.12). Significant predictors of LAA thrombus in the whole cohort by univariate analysis were ≥65 years of age (1.051, P=0.017), acute heart failure (2.394, P=0.038), and history of coronary artery/ peripheral vascular disease (2.7, P= 0.019). Notably neither duration of symptoms nor CHA2DS2-VASc score significantly predicted LAA thrombus. Inmultivariate analysis, only age ≥65 was found to be a significant predictor of LAA thrombus.
CONCLUSIONS: LAA thrombus in patients presenting within 48 hours of AF symptoms onset is not uncommon. Duration of symptoms is not reliable for excluding LAA thrombus.

Entities:  

Keywords:  Atrial fibrillation; Duration; Thrombus

Year:  2021        PMID: 34950371      PMCID: PMC8691273          DOI: 10.4022/jafib.20200481

Source DB:  PubMed          Journal:  J Atr Fibrillation        ISSN: 1941-6911


  19 in total

Review 1.  Atrial fibrillation and left atrial thrombus: an insufferable odd couple.

Authors:  J T Lie
Journal:  Am Heart J       Date:  1988-11       Impact factor: 4.749

2.  Strokes after cardioversion of atrial fibrillation--The FibStroke study.

Authors:  Antti Palomäki; Pirjo Mustonen; Juha E K Hartikainen; Ilpo Nuotio; Tuomas Kiviniemi; Antti Ylitalo; Päivi Hartikainen; Heidi Lehtola; Riho Luite; K E Juhani Airaksinen
Journal:  Int J Cardiol       Date:  2015-10-20       Impact factor: 4.164

3.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.

Authors:  Paulus Kirchhof; Stefano Benussi; Dipak Kotecha; Anders Ahlsson; Dan Atar; Barbara Casadei; Manuel Castella; Hans-Christoph Diener; Hein Heidbuchel; Jeroen Hendriks; Gerhard Hindricks; Antonis S Manolis; Jonas Oldgren; Bogdan Alexandru Popescu; Ulrich Schotten; Bart Van Putte; Panagiotis Vardas
Journal:  Eur Heart J       Date:  2016-08-27       Impact factor: 29.983

4.  Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS).

Authors: 
Journal:  Eur Heart J       Date:  2021-02-01       Impact factor: 29.983

Review 5.  The Epidemiology of Atrial Fibrillation and Stroke.

Authors:  Francesca Pistoia; Simona Sacco; Cindy Tiseo; Diana Degan; Raffaele Ornello; Antonio Carolei
Journal:  Cardiol Clin       Date:  2016-03-18       Impact factor: 2.213

6.  Thromboembolic risk in 16 274 atrial fibrillation patients undergoing direct current cardioversion with and without oral anticoagulant therapy.

Authors:  Morten Lock Hansen; Rikke Malene H G Jepsen; Jonas Bjerring Olesen; Martin Huth Ruwald; Deniz Karasoy; Gunnar Hilmar Gislason; Jim Hansen; Lars Køber; Steen Husted; Christian Torp-Pedersen
Journal:  Europace       Date:  2014-09-17       Impact factor: 5.214

7.  Thromboembolic complications after cardioversion of acute atrial fibrillation: the FinCV (Finnish CardioVersion) study.

Authors:  K E Juhani Airaksinen; Toni Grönberg; Ilpo Nuotio; Marko Nikkinen; Antti Ylitalo; Fausto Biancari; Juha E K Hartikainen
Journal:  J Am Coll Cardiol       Date:  2013-07-10       Impact factor: 24.094

8.  Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation.

Authors:  A L Klein; R A Grimm; R D Murray; C Apperson-Hansen; R W Asinger; I W Black; R Davidoff; R Erbel; J L Halperin; D A Orsinelli; T R Porter; M F Stoddard
Journal:  N Engl J Med       Date:  2001-05-10       Impact factor: 91.245

9.  Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: a transesophageal echocardiographic study.

Authors:  M F Stoddard; P R Dawkins; C R Prince; N M Ammash
Journal:  J Am Coll Cardiol       Date:  1995-02       Impact factor: 24.094

10.  Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial.

Authors:  Christoph Stellbrink; Uwe Nixdorff; Thomas Hofmann; Walter Lehmacher; Werner Günther Daniel; Peter Hanrath; Christoph Geller; Andreas Mügge; Walter Sehnert; Caroline Schmidt-Lucke; Jan-André Schmidt-Lucke
Journal:  Circulation       Date:  2004-02-16       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.